Daniel C. Liebler, Ph.D.
Director, Jim Ayers Institute for Precancer Detection and Diagnosis
Ingram Professor of Cancer Research
Professor of Biochemistry, Pharmacology, and Biomedical Informatics
Director, Center in Molecular Toxicology
Vanderbilt University Medical Center
465 21st Avenue South, U1213 MRB III
Nashville , TN 37232-6350
Daniel C. Liebler is Ingram Professor of Cancer Research and Professor of Biochemistry, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine. After completing his doctoral training in pharmacology at Vanderbilt and postdoctoral training in biochemistry at Oregon State, he served on the faculty at the University of Arizona prior to joining the Department of Biochemistry and the Vanderbilt-Ingram Cancer Center in 2003. He is Director of the Jim Ayers Institute for Precancer Detection and Diagnosis at Vanderbilt, which is dedicated to the advancement of cancer diagnostics. He leads the Vanderbilt program in the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) network, which is integrating proteomics with genomic technologies to understand the molecular drivers of cancer. Dr. Liebler is also the co-Director of the Vanderbilt Biomarker Developmental Laboratory in the NCI Early Detection Research Network. Dr. Liebler's research program has focused for over 25 years on toxicology, chemical biology and cancer biology, with an emphasis on application of mass spectrometry and proteomics.
- B.S. Chemistry, Villanova (1980)
- Ph.D. Pharmacology, Vanderbilt (1984)